ArticleAPL bioengineering2025
Peptide coacervates as intracellular delivery vehicles for synergistic cancer photothermal- and chemo-therapies.
Article in APL bioengineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Functionalized Coacervates for Cancer Therapy: Advances and Prospects in Phase-Separation-Based Intelligent Drug Delivery.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Reversible Nucleolar Complex Coacervation by Short Cationic Peptides.Journal of the American Chemical Society · 2026Article
- MgChem & bio engineering · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intracellular delivery of large molecular weight therapeutics poses a significant challenge in targeted cancer therapy, as conventional delivery vehicles often fail to achieve efficient cellular uptake and controlled release. This study presents a solution using GW26 coacervate microdroplets (CMs), a peptide-based system, as a dual-function platform that not only facilitates the controlled release of therapeutic cargos but also enhances cancer cell death through photothermal therapy (PTT). GW26 CMs exhibit high recruiting efficiency of photothermal (PT) materials-chlorin e6 (Ce6) and gold nanorods-with over 80% efficiency. These CMs demonstrate high cellular uptake in tumor cells, with 98% of CT26 colon carcinoma cells successfully internalizing Ce6-loaded CMs. Upon near-infrared laser irradiation, the PT materials generate localized heat within the therapeutic range for PTT, triggering coacervate disassembly, concomitant cargo release, and death of different human cancer cells, including cervical cancer cells HeLa, colon cancer cells HCT116, and colorectal adenocarcinoma cells HT29. The co-recruitment of the cytotoxic protein saporin enables synergistic PT and chemotherapeutic cancer treatments among all these cells, further enhancing the therapeutic effect, in some cases exhibiting a near-complete loss in cell viability. This approach combines efficient recruitment, controlled cargo release, and enhanced therapeutic efficacy, positioning GW26 CMs as a promising platform for multimodal cancer therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.